Where is Innovent Biologics headquartered?

Innovent Biologics is located in Suzhou, jiangsu province.

Who invested in Innovent Biologics?

Innovent Biologics has 13 investors including Geekdom Fund And Geekdom Fund.

How much funding has Innovent Biologics raised to date?

Innovent Biologics has raised ____.

When was the last funding round for Innovent Biologics?

Innovent Biologics closed its lastf unding roundon Jul 19, 2017 from a Convertible Note round.

Company Information
Company Timeline (Coming Soon)

innoventbio.com

Innovent Biologics

Innovent Biologics engages in research and development of monoclonal antibody drugs for cancer and autoimmune diseases.

Business Model:

Revenue: $588.9M

Employees: 1,001-5,000

Geographic Data

Address: 168 Dongping Street

City: Suzhou

State: jiangsu province

Zip: 215123

Country: CN

Financial Info

Stage:

post ipo equity

Raised Last:

$308M

Raised Total:

$868M

Social

Facebook

Twitter

Crunchbase

Metrics

1,355,465Website Global Rank

20,738Website Monthly Traffic

Twitter Followers

Description

Innovent Biologics engages in research and development of monoclonal antibody drugs for cancer and autoimmune diseases.

Contact Phone:

Contact Email:

IPO Details

Innovent Biologics went public on 10/24/2018 on the Hong Kong Stock Exchange

Listed Exchange:
Hong Kong Stock Exchange

IPO Date:
10/24/2018

IPO Valuation:
$2B

Ticker Symbol:
1801

IPO Price:
$1.7830586470691772/share

Amount Raised:
$421M

Live

Opened: -/share

EBITDA	-
Total Cash	-
Total Debt	-
Total Revenue	-
Total Profit (Gross)	-
PE Ratio	-

Investments

Announced Date	Company	Transaction	Money Raised
12/2021	AnHeart Therapeutics	Series B	0
12/2021	AnHeart Therapeutics	Series B	0

Funding Rounds

Announced Date	Transaction	Number of Investors	Money Raised	Lead Investors
4/2018	Series E	9	$150M	Cormorant Asset Management Rock Springs Capital Taikang Life Insurance Hillhouse Capital Group Capital Group Private Markets Temasek Holdings Legend Capital Lilly Asia Ventures Ally Bridge Group Capital Group Private Markets Cormorant Asset Management Rock Springs Capital Taikang Life Insurance Hillhouse Capital Group Capital Group Private Markets Temasek Holdings Legend Capital Lilly Asia Ventures Ally Bridge Group Capital Group Private Markets
1/2015	Series C	7	$115M	Legend Capital Temasek Holdings Lilly Asia Ventures Hillhouse Capital Group Frontline BioVentures F-Prime Capital Eight Roads Ventures Legend Capital
11/2016	Series D	8	$260M	SDIC Fund Management China Life Investment Holding Hillhouse Capital Group Legend Capital Milestone Ping An Ventures Taikang Life Insurance Temasek Holdings SDIC Fund Management
10/2011	Series A	1	$5M	F-Prime Capital F-Prime Capital
10/2018	IPO		$421M
10/2019	Secondary Offering		$300M
8/2022	Post-IPO Equity		$0	Sanofi Sanofi
11/2012	Series B	3	$30M	Lilly Asia Ventures F-Prime Capital Eight Roads Ventures
1/2015	Series C		$100M	Legend Capital Temasek Holdings Fidelity Growth Partners Asia Lilly Asia Ventures Frontline Bioventures
8/2022	Post-IPO Equity	1	$308.3M	Sanofi Sanofi

Acquisitions

Announced Date	Name	Price

Employee Demographics

Employee Departments

Employee States

Similar Companies

Uniview Singapore VEID	Revenue: 0 - 100000 Employees: Industry: Software	Details
Konkuk University Medical Center	Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education	Details
Daemon Technologies	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain	Details
Ace International Trade	Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial	Details
An Hòa Communications	Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising	Details